Aminoglycosides Monotherapy as First-Line Treatment for Febrile Urinary Tract Infection in Children.

Abstract

We report a retrospective monocentric descriptive study performed in CHI Creteil for 20 months to describe the management and outcome of amikacin monotherapy as an alternative to third-generation cephalosporins for empiric treatment of febrile urinary tract infection (FUTI) in children. Data were analyzed for 151 children, and 90 selected cases were classified as certain or highly probable FUTI. Escherichia coli infection was found in 89 cases. In all patients, fever was resolved within 72 hours after beginning amikacin treatment. Only 5.3% of children were febrile after 48 hours. The mean amikacin treatment duration was 3.05 ± 0.13 days before oral treatment began (guided by antibiotic susceptibility testing). Amikacin monotherapy seems effective for the initial management of FUTI in children.

• Authors: Nora Poey, Fouad Madhi, Sandra Biscardi, Stéphane Béchet, Robert Cohen
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 36 Issue 11 Pg. 1104-1107 (Nov 2017) ISSN: 1532-0987 [Electronic] United States
• PMID: 28498305 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Amikacin

Topics

• Adolescent
• Amikacin (pharmacology, therapeutic use)
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Child
• Child, Preschool
• Drug Resistance, Multiple, Bacterial
• Escherichia coli (drug effects)
• Escherichia coli Infections (drug therapy, microbiology)
• Female
• Fever
• Humans
• Infant
• Infant, Newborn
• Male
• Microbial Sensitivity Tests
• Retrospective Studies
• Urinary Tract Infections (drug therapy, microbiology)